Millennium Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-179,333
| Closed | -$3.32M | – | 6802 |
|
|
2023
Q3 | $3.32M | Sell |
179,333
-412,000
| -70% | -$4.66M | ﹤0.01% | 3099 |
|
|
2023
Q2 | $6.54M | Sell |
591,333
-91,073
| -13% | -$1.27M | ﹤0.01% | 2407 |
|
|
2023
Q1 | $9.16M | Sell |
682,406
-294,300
| -30% | -$5.09M | 0.01% | 2049 |
|
|
2022
Q4 | $12.1M | Sell |
976,706
-201,043
| -17% | -$2.85M | 0.01% | 1919 |
|
|
2022
Q3 | $16.4M | Buy |
1,177,749
+845,142
| +254% | +$13.6M | 0.01% | 1549 |
|
|
2022
Q2 | $4.59M | Sell |
332,607
-155,659
| -32% | -$2.49M | ﹤0.01% | 2896 |
|
|
2022
Q1 | $7.94M | Sell |
488,266
-71,412
| -13% | -$1.12M | ﹤0.01% | 2416 |
|
|
2021
Q4 | $9.12M | Buy |
+559,678
| New | +$9.43M | ﹤0.01% | 2238 |
|
|
2021
Q3 | – | Sell |
-25,948
| Closed | -$518K | – | 7415 |
|
|
2021
Q2 | $518K | Buy |
25,948
+3,115
| +14% | +$61.8K | ﹤0.01% | 5277 |
|
|
2021
Q1 | $527K | Sell |
22,833
-77,875
| -77% | -$2.17M | ﹤0.01% | 4785 |
|
|
2020
Q4 | $2.49M | Buy |
+100,708
| New | +$3.34M | ﹤0.01% | 3064 |
|
|
2020
Q2 | – | Sell |
-141,662
| Closed | -$8.92M | – | 4734 |
|
|
2020
Q1 | $8.92M | Buy |
141,662
+83,490
| +144% | +$7.5M | 0.02% | 932 |
|
|
2019
Q4 | $7.21M | Buy |
+58,172
| New | +$5.21M | 0.01% | 1630 |
|
|
2019
Q3 | – | Sell |
-5,966
| Closed | -$475K | – | 4655 |
|
|
2019
Q2 | $475K | Sell |
5,966
-8,341
| -58% | -$747K | ﹤0.01% | 3270 |
|
|
2019
Q1 | $1.6M | Buy |
14,307
+10,188
| +247% | +$1.11M | ﹤0.01% | 2556 |
|
|
2018
Q4 | $415K | Sell |
4,119
-6,382
| -61% | -$662K | ﹤0.01% | 3067 |
|
|
2018
Q3 | $1.33M | Sell |
10,501
-66,008
| -86% | -$6.99M | ﹤0.01% | 2708 |
|
|
2018
Q2 | $6.42M | Sell |
76,509
-158,671
| -67% | -$11.6M | 0.01% | 1633 |
|
|
2018
Q1 | $14.5M | Buy |
235,180
+147,719
| +169% | +$8.9M | 0.02% | 1095 |
|
|
2017
Q4 | $5.11M | Sell |
87,461
-1,358
| -2% | -$85.6K | 0.01% | 1734 |
|
|
2017
Q3 | $5.16M | Sell |
88,819
-100,764
| -53% | -$10.9M | 0.01% | 1655 |
|
|
2017
Q2 | $23M | Buy |
189,583
+166,029
| +705% | +$19.2M | 0.04% | 609 |
|
|
2017
Q1 | $2.66M | Buy |
+23,554
| New | +$2.75M | ﹤0.01% | 1831 |
|
|
2016
Q4 | – | Sell |
-87,028
| Closed | -$10.4M | – | 3844 |
|
|
2016
Q3 | $14.3M | Buy |
+87,028
| New | +$13.7M | 0.02% | 733 |
|
|
2016
Q2 | – | Sell |
-131,871
| Closed | -$19.2M | – | 3699 |
|
|
2016
Q1 | $16.9M | Buy |
131,871
+125,521
| +1,977% | +$14.8M | 0.04% | 556 |
|
|
2015
Q4 | $948K | Buy |
+6,350
| New | +$1.07M | ﹤0.01% | 2332 |
|
|
2015
Q3 | – | Sell |
-15,095
| Closed | -$3.32M | – | 3813 |
|
|
2015
Q2 | $3.64M | Sell |
15,095
-328,677
| -96% | -$87.5M | 0.01% | 1578 |
|
|
2015
Q1 | $97M | Sell |
343,772
-108,541
| -24% | -$23.5M | 0.18% | 98 |
|
|
2014
Q4 | $70.6M | Buy |
452,313
+150,301
| +50% | +$27.8M | 0.15% | 139 |
|
|
2014
Q3 | $71.5M | Buy |
302,012
+293,732
| +3,547% | +$74.9M | 0.18% | 104 |
|
|
2014
Q2 | $1.96M | Sell |
8,280
-91,161
| -92% | -$24M | 0.01% | 1797 |
|
|
2014
Q1 | $32.8M | Sell |
99,441
-299,086
| -75% | -$101M | 0.1% | 259 |
|
|
2013
Q4 | $27.2M | Buy |
398,527
+98,041
| +33% | +$5.67M | 0.09% | 242 |
|
|
2013
Q3 | $20.7M | Buy |
300,486
+148,392
| +98% | +$7.33M | 0.07% | 331 |
|
|
2013
Q2 | $6.82M | Buy |
+152,094
| New | +$5.2M | 0.02% | 836 |
|
Millennium Management's ICPT Position: Q4 2023 in Review
Millennium Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 179,333 shares — an estimated $3.32M sold.
Millennium Management first reported a position in ICPT in Q2 2013 and held it in 35 quarters. The position peaked at $97M in Q1 2015. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Millennium Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Millennium Management sold 179,333 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $3.32M.
- Millennium Management first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 35 quarters.
- Millennium Management's Intercept Pharmaceuticals, Inc. position peaked at $97M in Q1 2015.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Millennium Management's 13F filing for Q4 2023, filed 14 Feb 2024.